DK1283735T4 - Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf - Google Patents

Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf

Info

Publication number: DK1283735T4
Authority: DK; Denmark
Prior art keywords: cells; insulin producing; pancreatic; prevention; diabetes mellitus
Prior art date: 2000-03-31

Application number

DK01927848.0T

Other languages

English (en)

Other versions

DK1283735T3 (da

Inventor

Konrad Glund

Hans-Ulrich Demuth

Original Assignee

Royalty Pharma Collection Trust

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-31

Filing date

2001-04-02

Publication date

2013-02-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22716142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1283735(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-02 Application filed by Royalty Pharma Collection Trust filed Critical Royalty Pharma Collection Trust

2009-04-06 Application granted granted Critical

2009-04-06 Publication of DK1283735T3 publication Critical patent/DK1283735T3/da

2013-02-04 Publication of DK1283735T4 publication Critical patent/DK1283735T4/da

Links

238000000034 method Methods 0.000 title abstract 2
230000005754 cellular signaling Effects 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
210000004153 islets of langerhan Anatomy 0.000 title 1
230000002265 prevention Effects 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 6
102000004877 Insulin Human genes 0.000 abstract 3
108090001061 Insulin Proteins 0.000 abstract 3
229940125396 insulin Drugs 0.000 abstract 3
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
230000004069 differentiation Effects 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000002919 epithelial cell Anatomy 0.000 abstract 1
230000002641 glycemic effect Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
210000004923 pancreatic tissue Anatomy 0.000 abstract 1
230000004962 physiological condition Effects 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Rheumatology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK01927848.0T 2000-03-31 2001-04-02 Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf DK1283735T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19406100P	2000-03-31	2000-03-31
PCT/EP2001/003725 WO2001072290A2 (en)	2000-03-31	2001-04-02	Method for the improvement of islet signaling in diabetes mellitus and for its prevention

Publications (2)

Publication Number	Publication Date
DK1283735T3 DK1283735T3 (da)	2009-04-06
DK1283735T4 true DK1283735T4 (da)	2013-02-04

Family

ID=22716142

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08172906.3T DK2055302T3 (da)	2000-03-31	2001-04-02	Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf
DK01927848.0T DK1283735T4 (da)	2000-03-31	2001-04-02	Fremgangsmåde til forbedring signalering af øceller ved diabetes mellitus og til forebyggelse deraf

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK08172906.3T DK2055302T3 (da)	2000-03-31	2001-04-02	Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf

Country Status (21)

Country	Link
US (5)	US6500804B2 (da)
EP (3)	EP2266665B1 (da)
JP (1)	JP2003528135A (da)
KR (2)	KR20080067009A (da)
CN (2)	CN101690815A (da)
AT (1)	ATE419036T1 (da)
AU (2)	AU2001254763A1 (da)
BR (1)	BR0109553A (da)
CA (1)	CA2400226C (da)
CY (1)	CY1108872T1 (da)
CZ (1)	CZ20023234A3 (da)
DE (1)	DE60137216D1 (da)
DK (2)	DK2055302T3 (da)
ES (3)	ES2320630T5 (da)
HU (1)	HU229042B1 (da)
IL (1)	IL151368A0 (da)
NO (1)	NO20024643L (da)
PT (3)	PT1283735E (da)
RU (1)	RU2261096C2 (da)
WO (1)	WO2001072290A2 (da)
ZA (1)	ZA200206460B (da)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020006899A1 (en) *	1998-10-06	2002-01-17	Pospisilik Andrew J.	Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
CA2304206A1 (en)	1997-09-29	1999-04-08	Point Therapeutics, Inc.	Stimulation of hematopoietic cells in vitro
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de) *	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6979697B1 (en) *	1998-08-21	2005-12-27	Point Therapeutics, Inc.	Regulation of substrate activity
US20030176357A1 (en) *	1998-10-06	2003-09-18	Pospisilik Andrew J.	Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US6890904B1 (en) *	1999-05-25	2005-05-10	Point Therapeutics, Inc.	Anti-tumor agents
DE19940130A1 (de) *	1999-08-24	2001-03-01	Probiodrug Ges Fuer Arzneim	Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
US20030040469A1 (en) *	2000-03-08	2003-02-27	Knudsen Liselotte Bjerre	Lowering serum lipids
AU2001254763A1 (en) *	2000-03-31	2001-10-08	Prosidion Limited	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
ZA200302394B (en) *	2000-10-27	2004-03-29	Probiodrug Ag	Method for the treatment of neurological and neuropsychological disorders.
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20030022816A1 (en) *	2001-03-07	2003-01-30	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
US20070293426A1 (en) *	2001-04-02	2007-12-20	Hans-Ulrich Demuth	Methods for improving islet signaling in diabetes mellitus and for its prevention
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention
GB0109146D0 (en) *	2001-04-11	2001-05-30	Ferring Bv	Treatment of type 2 diabetes
US7368421B2 (en) *	2001-06-27	2008-05-06	Probiodrug Ag	Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) *	2001-06-27	2003-07-10	Von Hoersten Stephan	Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
CN1723196A (zh)	2001-06-27	2006-01-18	史密丝克莱恩比彻姆公司	作为二肽酶抑制剂的氟代吡咯烷
EP1492525A2 (en) *	2001-08-16	2005-01-05	Probiodrug AG	Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US6844316B2 (en) *	2001-09-06	2005-01-18	Probiodrug Ag	Inhibitors of dipeptidyl peptidase I
EP1487471A4 (en) *	2001-11-26	2010-03-10	Tufts College	METHOD FOR TREATING AUTOIMMUNE DISEASES AND ASSOCIATED REAGENTS
SK3622004A3 (sk) *	2002-02-28	2005-02-04	Prosidion Limited	Inhibítory DPIV na báze glutaminylu
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
KR20050048542A (ko)	2002-06-07	2005-05-24	와라타 파마수티컬즈, 인크.	당뇨병의 치료를 위한 조성물 및 방법
PT1528931E (pt) *	2002-08-09	2008-08-13	Prosidion Ltd	Inibidores da dipeptidilpeptidase iv para a diminuição da taxa de aumento de peso crónico
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2004024184A1 (ja) *	2002-09-11	2004-03-25	Takeda Pharmaceutical Company Limited	徐放性製剤
US20040058876A1 (en) *	2002-09-18	2004-03-25	Torsten Hoffmann	Secondary binding site of dipeptidyl peptidase IV (DP IV)
EP1543023B1 (en) *	2002-09-18	2010-03-17	Prosidion Limited	Secondary binding site of dipeptidyl peptidase iv (dp iv)
MXPA05004202A (es) *	2002-10-22	2005-09-20	Waratah Pharmaceuticals Inc	Tratamiento de la diabetes.
DE10308352A1 (de)	2003-02-27	2004-09-09	Aventis Pharma Deutschland Gmbh	Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308355A1 (de)	2003-02-27	2004-12-23	Aventis Pharma Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de)	2003-02-27	2004-11-25	Aventis Pharma Deutschland Gmbh	1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de)	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en)	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
NZ568459A (en) *	2003-05-05	2009-06-26	Probiodrug Ag	Use of effectors of glutaminyl and glutamate cyclases
JP4806628B2 (ja) *	2003-05-05	2011-11-02	プロビオドルグエージー	グルタミニルシクラーゼ阻害剤
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
WO2005030751A2 (en) *	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2007505121A (ja)	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
CA2542419C (en) *	2003-10-15	2013-06-04	Probiodrug Ag	Use of glutamyl cyclase inhibitors in the treatment of familial british dementia and familial danish dementia
ES2231036B1 (es) *	2003-10-31	2006-07-01	Encofrados J. Alsina, S.A.	Puntal.
US20050171112A1 (en) *	2003-11-03	2005-08-04	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) *	2003-11-03	2010-04-22	Probiodrug Ag	Novel compounds for the treatment of neurological disorders
KR20150132601A (ko)	2003-11-17	2015-11-25	노파르티스 아게	디펩티딜 펩티다제 ⅳ 억제제의 용도
EP3366283B1 (en)	2004-01-20	2021-09-01	Novartis AG	Direct compression formulation and process
US7241787B2 (en) *	2004-01-25	2007-07-10	Sanofi-Aventis Deutschland Gmbh	Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
KR101099206B1 (ko)	2004-02-05	2011-12-27	프로비오드룩 아게	신규한 글루타미닐 시클라제 저해제
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
KR101292707B1 (ko) *	2004-02-23	2013-08-02	트러스티즈 오브 터프츠 칼리지	디펩티딜펩티다아제 ⅳ의 억제제
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
EA013427B1 (ru)	2004-03-15	2010-04-30	Такеда Фармасьютикал Компани Лимитед	Ингибиторы дипептидилпептидазы
EP1586573B1 (en)	2004-04-01	2007-02-07	Sanofi-Aventis Deutschland GmbH	Oxadiazolones, processes for their preparation and their use as pharmaceuticals
JP2008501714A (ja)	2004-06-04	2008-01-24	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
WO2006012395A2 (en)	2004-07-23	2006-02-02	Susan Marie Royalty	Peptidase inhibitors
EP1782832A4 (en) *	2004-08-26	2009-08-26	Takeda Pharmaceutical	MEANS FOR THE TREATMENT OF DIABETES
US20060063719A1 (en) *	2004-09-21	2006-03-23	Point Therapeutics, Inc.	Methods for treating diabetes
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1828192B1 (en)	2004-12-21	2014-12-03	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN101277949A (zh)	2005-04-22	2008-10-01	阿兰托斯制药控股公司	二肽基肽酶-ⅳ抑制剂
DE102005026762A1 (de)	2005-06-09	2006-12-21	Sanofi-Aventis Deutschland Gmbh	Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
MY152185A (en)	2005-06-10	2014-08-29	Novartis Ag	Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20090202497A1 (en) *	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
EP2073810B1 (en) *	2006-09-13	2011-08-31	Takeda Pharmaceutical Company Limited	Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
AU2006290205B2 (en) *	2005-09-14	2012-12-13	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
US20070060529A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
PL1931350T5 (pl) *	2005-09-14	2021-11-15	Takeda Pharmaceutical Company Limited	Podanie inhibitorów dipeptydylo-peptydazy
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
RU2008116578A (ru) *	2005-09-30	2009-11-10	Новартис АГ (CH)	Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
CA2625150A1 (en) *	2005-10-07	2007-04-19	Waratah Pharmaceuticals, Inc.	Combined use of dpp-iv inhibitors and gastrin compounds
AT502717A1 (de) *	2005-11-09	2007-05-15	Omnica Gmbh	Pharmazeutische verwendung einer verbindung
GB0526291D0 (en)	2005-12-23	2006-02-01	Prosidion Ltd	Therapeutic method
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US20100029941A1 (en) *	2006-03-28	2010-02-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
PE20080251A1 (es) *	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
US20080293644A1 (en) *	2007-04-27	2008-11-27	Thomas Eidenberger	Guava extract
AU2008290582B2 (en) *	2007-08-17	2014-08-14	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) *	2008-08-15	2019-12-18	Boehringer Ingelheim Int	Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8241410B1 (en)	2008-10-17	2012-08-14	Alchem Environmental LLC	Ancillary embodiments and modifications to a polyphasic pressurized homogenizer
US9144205B2 (en)	2008-10-17	2015-09-29	Alchem Environmental Ip Llc	Hydroponics applications and ancillary modifications to a polyphasic pressurized homogenizer
US9757683B1 (en)	2008-10-17	2017-09-12	Alchem Environmental Ip Llc	Polyphasic pressurized homogenizer (PPH) and methods for methane purification
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US9655003B2 (en) *	2009-03-19	2017-05-16	Georgia Tech Research Corporation	Systems and methods for improved wireless interface aggregation
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102807568B (zh) *	2011-05-31	2015-11-25	正大天晴药业集团股份有限公司	噻二唑衍生物类dpp-iv抑制剂
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
CN105315301B (zh) *	2014-08-05	2018-04-03	连云港润众制药有限公司	噻二唑类dpp‑ⅳ抑制剂的枸橼酸盐
HK1249847A1 (zh)	2015-03-09	2018-11-16	Intekrin Therapeutics, Inc.	用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
CN106620704A (zh) *	2016-11-04	2017-05-10	广州赛莱拉干细胞科技股份有限公司	一种治疗糖尿病的制剂及其制备方法和应用
WO2018162722A1 (en)	2017-03-09	2018-09-13	Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke	Dpp-4 inhibitors for use in treating bone fractures
KR20200036808A (ko)	2017-04-03	2020-04-07	코히러스 바이오사이언시스, 인크.	진행성 핵상 마비 치료를 위한 PPARγ 작용제
CN112386217A (zh) *	2019-08-14	2021-02-23	关永晖	一种膀胱镜注射针

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2961377A (en)	1957-08-05	1960-11-22	Us Vitamin Pharm Corp	Oral anti-diabetic compositions and methods
US3174901A (en) *	1963-01-31	1965-03-23	Jan Marcel Didier Aron Samuel	Process for the oral treatment of diabetes
DE2009743A1 (de)	1970-03-03	1971-09-16	Farbenfabriken Bayer Ag, 5090 Leverkusen	Substituierte Biguanide mit antihyperglykämischer Wirkung
US3879541A (en) *	1970-03-03	1975-04-22	Bayer Ag	Antihyperglycemic methods and compositions
US3960949A (en)	1971-04-02	1976-06-01	Schering Aktiengesellschaft	1,2-Biguanides
CH602612A5 (da)	1974-10-11	1978-07-31	Hoffmann La Roche
US4935493A (en)	1987-10-06	1990-06-19	E. I. Du Pont De Nemours And Company	Protease inhibitors
US5433955A (en)	1989-01-23	1995-07-18	Akzo N.V.	Site specific in vivo activation of therapeutic drugs
US5462928A (en) *	1990-04-14	1995-10-31	New England Medical Center Hospitals, Inc.	Inhibitors of dipeptidyl-aminopeptidase type IV
JPH04334357A (ja)	1991-05-02	1992-11-20	Fujirebio Inc	酵素阻害作用を有するアシル誘導体
DK0610317T3 (da)	1991-10-22	2001-02-19	New England Medical Center Inc	Inhibitorer af dipeptidyl-aminopeptidase type IV
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
IL106998A0 (en)	1992-09-17	1993-12-28	Univ Florida	Brain-enhanced delivery of neuroactive peptides by sequential metabolism
FR2696740B1 (fr)	1992-10-13	1994-12-30	Dospharma Sa	Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments.
WO1995011689A1 (en)	1993-10-29	1995-05-04	Trustees Of Tufts College	Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5543396A (en)	1994-04-28	1996-08-06	Georgia Tech Research Corp.	Proline phosphonate derivatives
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5614379A (en)	1995-04-26	1997-03-25	Eli Lilly And Company	Process for preparing anti-obesity protein
DE122010000020I1 (de) †	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
CZ389398A3 (cs)	1996-05-29	1999-07-14	Prototek, Inc.	Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5827898A (en) *	1996-10-07	1998-10-27	Shaman Pharmaceuticals, Inc.	Use of bisphenolic compounds to treat type II diabetes
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
AR016751A1 (es)	1996-11-22	2001-08-01	Athena Neurosciences Inc	Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo
US6001155A (en)	1997-03-17	1999-12-14	Pease; John R.	Polyphasic pressurized homogenizer
EP2823812A1 (en)	1998-02-02	2015-01-14	Trustees Of Tufts College	Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes
EP1062222A1 (en)	1998-03-09	2000-12-27	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de) *	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
AU4854999A (en)	1998-07-02	2000-01-24	Invitro Diagnostics, Inc.	Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
DE19834591A1 (de) *	1998-07-31	2000-02-03	Probiodrug Ges Fuer Arzneim	Verfahren zur Steigerung des Blutglukosespiegels in Säugern
WO2000053171A1 (en)	1999-03-05	2000-09-14	Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.	Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
US6107317A (en) *	1999-06-24	2000-08-22	Novartis Ag	N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6172081B1 (en) *	1999-06-24	2001-01-09	Novartis Ag	Tetrahydroisoquinoline 3-carboxamide derivatives
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US7064145B2 (en) *	2000-02-25	2006-06-20	Novo Nordisk A/S	Inhibition of beta cell degeneration
JP2003523396A (ja)	2000-02-25	2003-08-05	ノボノルディスクアクティーゼルスカブ	ベータ細胞変性の抑制
AU2001254763A1 (en) *	2000-03-31	2001-10-08	Prosidion Limited	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US6890905B2 (en) *	2001-04-02	2005-05-10	Prosidion Limited	Methods for improving islet signaling in diabetes mellitus and for its prevention

2001
- 2001-04-02 AU AU2001254763A patent/AU2001254763A1/en not_active Abandoned
- 2001-04-02 IL IL15136801A patent/IL151368A0/xx active IP Right Grant
- 2001-04-02 KR KR1020087014806A patent/KR20080067009A/ko not_active Ceased
- 2001-04-02 PT PT01927848T patent/PT1283735E/pt unknown
- 2001-04-02 DK DK08172906.3T patent/DK2055302T3/da active
- 2001-04-02 KR KR1020027013054A patent/KR20030019337A/ko not_active Ceased
- 2001-04-02 EP EP10179515.1A patent/EP2266665B1/en not_active Expired - Lifetime
- 2001-04-02 ES ES01927848T patent/ES2320630T5/es not_active Expired - Lifetime
- 2001-04-02 EP EP01927848A patent/EP1283735B2/en not_active Expired - Lifetime
- 2001-04-02 EP EP08172906.3A patent/EP2055302B1/en not_active Expired - Lifetime
- 2001-04-02 JP JP2001570251A patent/JP2003528135A/ja active Pending
- 2001-04-02 AT AT01927848T patent/ATE419036T1/de active
- 2001-04-02 DK DK01927848.0T patent/DK1283735T4/da active
- 2001-04-02 CZ CZ20023234A patent/CZ20023234A3/cs unknown
- 2001-04-02 CN CN200910208114A patent/CN101690815A/zh active Pending
- 2001-04-02 ES ES10179515.1T patent/ES2582376T3/es not_active Expired - Lifetime
- 2001-04-02 BR BR0109553-6A patent/BR0109553A/pt not_active Application Discontinuation
- 2001-04-02 DE DE60137216T patent/DE60137216D1/de not_active Expired - Lifetime
- 2001-04-02 CA CA002400226A patent/CA2400226C/en not_active Expired - Lifetime
- 2001-04-02 US US09/824,622 patent/US6500804B2/en not_active Expired - Fee Related
- 2001-04-02 RU RU2002129014/14A patent/RU2261096C2/ru active
- 2001-04-02 ES ES08172906.3T patent/ES2525041T3/es not_active Expired - Lifetime
- 2001-04-02 CN CN01807402A patent/CN1420797A/zh active Pending
- 2001-04-02 PT PT101795151T patent/PT2266665T/pt unknown
- 2001-04-02 WO PCT/EP2001/003725 patent/WO2001072290A2/en not_active Ceased
- 2001-04-02 HU HU0204459A patent/HU229042B1/hu unknown
- 2001-04-02 PT PT81729063T patent/PT2055302E/pt unknown
2002
- 2002-07-16 US US10/196,038 patent/US20020198242A1/en not_active Abandoned
- 2002-07-22 US US10/200,870 patent/US20030008905A1/en not_active Abandoned
- 2002-08-13 ZA ZA200206460A patent/ZA200206460B/en unknown
- 2002-09-27 NO NO20024643A patent/NO20024643L/no unknown
2003
- 2003-10-01 US US10/676,832 patent/US20050222221A1/en not_active Abandoned
2004
- 2004-08-02 US US10/910,176 patent/US20050014703A1/en not_active Abandoned
2006
- 2006-06-01 AU AU2006202344A patent/AU2006202344B2/en not_active Expired
2009
- 2009-03-12 CY CY20091100280T patent/CY1108872T1/el unknown

Also Published As

Publication number	Publication date
CN1420797A (zh)	2003-05-28
EP2266665A1 (en)	2010-12-29
EP2266665B1 (en)	2016-05-11
US20050014703A1 (en)	2005-01-20
IL151368A0 (en)	2003-04-10
NO20024643L (no)	2002-11-05
HK1051007A1 (en)	2003-07-18
PT1283735E (pt)	2009-03-19
KR20080067009A (ko)	2008-07-17
HUP0204459A3 (en)	2006-01-30
EP1283735B1 (en)	2008-12-31
CA2400226A1 (en)	2001-10-04
EP2055302B1 (en)	2014-09-10
EP1283735A2 (en)	2003-02-19
HU229042B1 (en)	2013-07-29
EP1283735B2 (en)	2012-10-24
PT2266665T (pt)	2016-07-07
PT2055302E (pt)	2014-12-03
US20010051646A1 (en)	2001-12-13
ES2582376T3 (es)	2016-09-12
US20030008905A1 (en)	2003-01-09
NO20024643D0 (no)	2002-09-27
KR20030019337A (ko)	2003-03-06
CA2400226C (en)	2007-01-02
BR0109553A (pt)	2003-06-03
US20050222221A1 (en)	2005-10-06
DK2055302T3 (da)	2014-10-27
CZ20023234A3 (cs)	2003-01-15
ATE419036T1 (de)	2009-01-15
ES2525041T3 (es)	2014-12-16
WO2001072290A2 (en)	2001-10-04
AU2006202344B2 (en)	2009-01-08
ZA200206460B (en)	2003-08-13
DE60137216D1 (de)	2009-02-12
ES2320630T5 (es)	2013-03-12
RU2261096C2 (ru)	2005-09-27
US20020198242A1 (en)	2002-12-26
DK1283735T3 (da)	2009-04-06
HUP0204459A2 (en)	2003-05-28
AU2006202344A1 (en)	2006-06-22
JP2003528135A (ja)	2003-09-24
EP2055302A1 (en)	2009-05-06
HK1130015A1 (en)	2009-12-18
CY1108872T1 (el)	2014-07-02
CN101690815A (zh)	2010-04-07
ES2320630T3 (es)	2009-05-27
WO2001072290A3 (en)	2002-03-14
AU2001254763A1 (en)	2001-10-08
US6500804B2 (en)	2002-12-31

Publication	Publication Date	Title
DK2055302T3 (da)	2014-10-27	Fremgangsmåde til forbedring af signalering af øceller ved diabetes mellitus og til forebyggelse deraf
MXPA02012763A (es)	2003-04-25	Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
GB0001449D0 (en)	2000-03-08	Compositions
CA2395165A1 (en)	2002-05-02	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
CY1108769T1 (el)	2014-04-09	Αναστολεις της διπεπτιδυλικης πεπτιδασης iv για μειωση του ρυθμου της χρονιας αυξησης βαρους
NO20083276L (no)	2000-02-17	Behandling av diabetes med tiazolidindion og sulfonylurea
WO2005060960A3 (en)	2005-11-17	Use of histamine to treat bone disease
NO996270L (no)	1999-12-17	Behandling av diabetes med tiazolidindion og <alfa>- glukosidaseinhibitor
WO2007014253A3 (en)	2007-06-14	Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
AU1908601A (en)	2001-06-04	Method and composition for the treatment of adenoviral ocular infections
CY1117624T1 (el)	2017-04-26	Μεθοδος για τη βελτιωση της σηματοδοτησης νησιδιων στον σακχαρωδη διαβητη και την προληψη
CO5150158A1 (es)	2002-04-29	Tratamiento antidiabetico novedoso
BRPI0408984A (pt)	2006-03-28	método para tratar uma condição de doença mediada por células neutrofìlicas em um paciente, e, uso de um composto de ligação de histamina
MX2007012991A (es)	2008-03-13	Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
WO2003041703A3 (en)	2003-07-31	Use of a flavonoid for the treatment of burns
WO2006081347B1 (en)	2007-02-22	Controlled release compositions comprising an antipsychotic agent
WO2006123178A3 (en)	2007-05-10	Methods and compositions for the treatment of viral diseases
ECSP982541A (es)	1999-02-11	Nuevo metodo de tratamiento ii
ECSP982535A (es)	1999-04-13	Nuevo metodo de tratamiento (i)
ECSP982592A (es)	1999-02-22	Nuevo metodo de tratamiento v
AP2000001787A0 (en)	2000-06-30	Use of thiazolidinediones for the treatment of hyperglycaemia.
MXPA04006675A (es)	2004-10-04	Composicion farmaceutica que comprende glitazona y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
ECSP982534A (es)	1999-02-11	Nuevo metodo de tratamiento
WO2007057897A3 (en)	2009-02-12	Pharmaceutical composition and method for regulating abnormal cellular proliferation